Pay in 4 interest-free payments of $6.65 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
The lead time may vary depending on the order volume and destination
Description Cagrilintide is an investigational, long-acting synthetic peptide that acts as a dual amylin and calcitonin receptor agonist (DACRA), primarily under development for the treatment of obesity and type 2 diabetes
CagriSema achieved 22.7% at 68 weeks while tirzepatide achieved 22.5% at 72 weeks
However: They are not first-line treatments for acute emergencies
US$ 19.98
US$ 29.14
US$ 26.06
US$ 20.00
US$ 26.61
US$ 20.21
US$ 22.46
